MTOR and Lymphadenopathy: This suggests that the mTOR pathway may be a key player in CD4+ T-cell senescence, and the use of rapamycin (RAPA) can lower the level of glycolysis by inhibiting the mTOR signaling pathway and promoting the number of naïve T-cells, thereby improving the immune function of the PASLI (p110δ-activating mutation causing senescent T-cells, lymphadenopathy, and immunodeficiency) patients [65].